Report of Foreign Issuer (6-k)
June 01 2020 - 07:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant
to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of June 2020
001-36203
(Commission File Number)
CAN-FITE BIOPHARMA LTD.
(Exact name of Registrant as specified in
its charter)
10 Bareket Street
Kiryat Matalon, P.O. Box 7537
Petach-Tikva 4951778, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
This Form 6-K and exhibits 99.1, 99.2
and 99.3 and the text under the heading “Financial Results”, the accompanying interim condensed consolidated
financial statements and “Forward Looking Statements” of the press release attached as Exhibit 99.4 to this Form
6-K are hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No.
333-227753) and Form F-3 (File Nos. 333-195124, 333-236064, 333-209037 and 333-220644), to be a part thereof from the date on
which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
On June 1, 2020, Can-Fite BioPharma
Ltd. (the” Company”) re-issued its consolidated financial statements for the year ended December 31, 2019 as a
result of the Company’s change in accounting method from International Financial Reporting Standards, as issued by the
International Accounting Standards Board, to generally accepted accounting principles in the United States of America
(“U.S. GAAP”).
The consolidated financial statements attached
hereto were prepared in accordance with U.S. GAAP. Such financial statements and accompanying Selected Financial Data and Operating
and Financial Review and Prospects attached hereto replace the consolidated financial statements and the Selected Financial Data
and Operating and Financial Review and Prospects included in the Company’s Annual Report on Form 20-F filed with the SEC
on March 27, 2020.
In addition, on June 1, 2020, the
Company issued a press release announcing that it reported financial results for the three months ended March 31, 2020 and
provided clinical and corporate updates. A copy of this press release is attached hereto as Exhibit 99.4 and is incorporated
herein by reference.
Attached hereto and incorporated by reference
herein are the following exhibits:
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: June 1, 2020
|
By:
|
/s/ Pnina Fishman
|
|
|
Pnina Fishman
|
|
|
Chief Executive Officer
|
3
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Feb 2024 to Mar 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2023 to Mar 2024